Hamed Mansoor Lakooraj - ۱Department of Clinical Pathology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran
Zohreh Khaki - Department of Clinical Pathology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran
Masoud Ghorbani - Pasteur Institute of Iran, Research and Production Complex, Department of Research and Development
Mehdi Shafiee Ardestani - ۳Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
Omid Dezfoulian - ۴Department of Pathobiology, Faculty of Veterinary Medicine, Lorestan University, Khorramabad, Iran

BACKGROUND: To achieve delivery of a drug to tumors, folic acid (FA) was used as a targeting ligand to change nanocarriers. Since the folate receptor has more expression in several tumor types such as breast cancer. OBJECTIVES: The present study aimed to evaluate the effect of Doxorubicine-G2-FA (Dox- G2-FA) with in vitro assays. The abbreviation of G2 represents the second generation of dendrimer synthesis. METHODS: For this purpose, Dox-G2-FA was synthesized and mass spectroscopy was used to confirm the synthesized component. Also, MTT assay, flow cytometry, and gene expression assay by real-time PCR were used to evaluate cell viability, apoptosis, and necrosis. RESULTS: In this study, the effect of Dox and Dox-G2-FA on the expression of Bax, Bcl2 genes showed that there was a significant decrease in the expression of the Bcl2 gene in the Dox-G2-FA group compared to Dox and control groups(   P<0.05). Also, the results of flow-cytometry showed that apoptosis in the presence of Dox-G2-FA was greater than in the Dox group (   P<0.05). CONCLUSIONS: Therefore, it seems that the effect of Dox-G2-FA on apoptosis is better than the effect of Dox usage alone.

Apoptosis, Bax, Bcl2, Breast Cancer, Doxorubicine-G2-folate